Grant Hawthorne
Direttore operativo presso NRG Therapeutics Ltd.
Provenienza dei contatti di primo grado di Grant Hawthorne
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Auspherix Ltd.
Auspherix Ltd. BiotechnologyHealth Technology Auspherix Ltd. operates as an early stage anti-infectives company which develops novel antibiotics to treat resistant bacterial diseases. The firm uses a library screening approach to identify drugs with novel mechanisms of action as antibiotics. The company was founded by Ian Charles and Dagmar Alber in 2013 and is headquartered in Stevenage, the United Kingdom.
7
| Extinct | Biotechnology | 7 |
NRG Therapeutics Ltd.
NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018.
7
| Holding Company | Miscellaneous Commercial Services | 7 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Grant Hawthorne tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
Chord Therapeutics SA
Chord Therapeutics SA BiotechnologyHealth Technology Chord Therapeutics SA is a clinical stage pharmaceutical company. It develops drugs for patients with rare, life-threatening and severely disabling diseases. The firm offers CRD1. The company was founded by Arthur Roach and is headquartered in Geneva, Switzerland. | Biotechnology | Chairman Director/Board Member Founder | |
Brandon Capital Partners Pty Ltd.
Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | Investment Managers | Private Equity Investor Private Equity Investor Director/Board Member | |
Imperial College London | College/University | Masters Business Admin Masters Business Admin | |
University of Oxford | College/University | Undergraduate Degree Undergraduate Degree | |
Longas Technologies Pty Ltd.
Longas Technologies Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Longas Technologies Pty Ltd. is engaged in developing next generation sequencing (NGS) technologies. The company was founded by Ian Charles, Aaron Darling, and Catherine Burke in 2015 and is headquartered in Sydney, Australia. | Miscellaneous Commercial Services | Chairman Founder | |
Touchstone Innovations Investment Management Ltd.
Touchstone Innovations Investment Management Ltd. Investment ManagersFinance Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London. | Investment Managers | Private Equity Analyst Director/Board Member | |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | Investment Managers | Private Equity Investor Private Equity Investor | |
Myricx Pharma Ltd.
Myricx Pharma Ltd. Miscellaneous Commercial ServicesCommercial Services Myricx Pharma Ltd. engages in the development of novel proprietary inhibitors of human N-myristoyltransferases. The company was founded by Ed Tate, Roberto Solari, and Andrew Bell in 2019 and is headquartered in Stevenage, the United Kingdom. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member | |
Artios Pharma Ltd.
Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Erasmus University Rotterdam | College/University | Masters Business Admin | |
University College London | College/University | Doctorate Degree | |
Molecular Vision Ltd.
Molecular Vision Ltd. Medical SpecialtiesHealth Technology Molecular Vision Ltd. develops low-cost, lab-quality, point of care, disposable diagnostic devices for medical testing. The company was founded by Donal D. C. Bradley in 2001 and is headquartered in York, the United Kingdom. | Medical Specialties | Director/Board Member | |
IP GROUP PLC | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Autifony Therapeutics Ltd.
Autifony Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Oxular Ltd.
Oxular Ltd. BiotechnologyHealth Technology Oxular Ltd. engages in research and experimental development on biotechnology. The firm develops retinal treatments to access specific small spaces in the eye and to provide drug distribution to tissues involved in retinal diseases. The company was founded by Tom Cavanagh and Ronald K. Yamamoto in 2014 and is headquartered in Oxford, the United Kingdom. | Biotechnology | Director/Board Member | |
Pulmocide Ltd.
Pulmocide Ltd. Pharmaceuticals: MajorHealth Technology Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Enterprise Therapeutics Ltd.
Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | Biotechnology | Director/Board Member | |
ARIX BIOSCIENCE PLC | Investment Managers | Chief Executive Officer | |
STORM Therapeutics Ltd.
STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Acesion Pharma ApS
Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Avilex Pharma ApS
Avilex Pharma ApS Pharmaceuticals: MajorHealth Technology Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Chairman | |
Maxygen ApS | Corporate Officer/Principal | ||
Novo Seeds
Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Investment Managers | Corporate Officer/Principal | |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Corporate Officer/Principal | |
LEO Pharma A/S
LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Corporate Officer/Principal | |
University of Virginia | College/University | Doctorate Degree | |
Rochester Christian University | College/University | Undergraduate Degree | |
TOUCHSTONE INNOVATIONS PLC | Investment Managers | Corporate Officer/Principal | |
University of Technology Sydney | College/University | Corporate Officer/Principal | |
The Isenberg School of Management | College/University | Graduate Degree | |
American School of Milan | College/University | Graduate Degree | |
Commonfund Capital, Inc.
Commonfund Capital, Inc. Investment ManagersFinance Commonfund Capital, Inc (Commonfund Capital) is a private equity and venture capital subsidiary of Commonfund Holding Co., Inc founded in 1988. The firm is headquartered in Wilton, Connecticut with additional offices in New York, California, London & China. | Investment Managers | Corporate Officer/Principal | |
OMEGA ALPHA SPAC | Financial Conglomerates | Founder | |
University of Massachusetts Amherst College of Natural Science | College/University | Undergraduate Degree | |
The University of Liverpool
The University of Liverpool Other Consumer ServicesConsumer Services The University of Liverpool operates as a university. It offers post graduate research, foundation courses, continuing and professional development, online study, and doctoral college. The company was founded in 1881 and is headquartered in Liverpool, the United Kingdom. | College/University | Doctorate Degree | |
KALEIDO BIOSCIENCES, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Harvard Medical School | College/University | Doctorate Degree | |
Wolfson Institute For Biomedical Research | Corporate Officer/Principal | ||
Ithree Institute | College/University | Director/Board Member | |
Quadram Institute Bioscience
Quadram Institute Bioscience Miscellaneous Commercial ServicesCommercial Services Quadram Institute Bioscience operates as a non-profit organization that provides food research for health and prevention of food related diseases. The organization serves science research base, industry, clinical practice via health and preventive medicine and evidence-based policy for government and industry. The company was founded in November 1986 and is headquartered in Norwich, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Contera Pharma ApS
Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Arrow Therapeutics Ltd.
Arrow Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Arrow Therapeutics Ltd. operates as a pharmaceutical company that focuses on research and development of novel antiviral drugs. Its products include novel antibacterial, antiviral, antifungal and preclinical compounds. The company was founded in 1998 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Founder | |
Norwich Research Partners LLP
Norwich Research Partners LLP Miscellaneous Commercial ServicesCommercial Services Norwich Research Partners LLP operates as a business community. The private company is based in Norwich, UK. The British company was founded in 2012. The CEO is David Parfrey. | Miscellaneous Commercial Services | Director/Board Member | |
GENUS PLC | Agricultural Commodities/Milling | Director/Board Member | |
University of Leicester | College/University | Doctorate Degree | |
Pheon Therapeutics Ltd.
Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | Biotechnology | Director/Board Member | |
ABINGDON HEALTH PLC | Medical Specialties | Private Equity Investor |
Statistiche
Distribuzione geografica
Regno Unito | 26 |
Stati Uniti | 10 |
Danimarca | 8 |
Australia | 5 |
Israele | 3 |
Settori
Health Technology | 20 |
Consumer Services | 15 |
Finance | 10 |
Commercial Services | 6 |
Process Industries | 2 |
Posizioni
Director/Board Member | 69 |
Corporate Officer/Principal | 17 |
Chairman | 11 |
Private Equity Investor | 11 |
Doctorate Degree | 9 |
Contatti più connessi
Insiders | |
---|---|
Claudio Nessi | 25 |
Bobby G. Soni | 23 |
Jonathan Leslie Tobin | 19 |
Stephen Thompson | 18 |
Roberto Solari | 10 |
Ian Charles | 10 |
Francesco Draetta | 9 |
Jonathan R. Savidge | 7 |
Jared Silverman | 3 |
Neil Miller | 3 |
Arthur Roach | 2 |
Richard Rutter | 1 |
- Borsa valori
- Insiders
- Grant Hawthorne
- Connessioni Società